Meanwhile, GLP-1 receptor antagonists such as liraglutide, semaglutide, ALT-801, and dulaglutide promote pancreatic insulin production and inhibit glucagon secretion in protecting against NAFLD development. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.